Natural Compound

Phenylethylamine (PEA)

β-Phenylethylamine (2-phenylethylamine, PEA)

Evidence TierBWADA PROHIBITED

tuneTypical Dose

200–500 mg per day

watchEffect Window

Extreme acute onset (5–15 min). Very short duration (15–30 min) due to rapid MAO-B degradation.

lockCompliance

WADA PROHIBITED

Overview

Clinical Summary

Phenylethylamine is a trace amine produced in the body and present in foods such as chocolate. It is used for transient mood and motivation effects, but it is rapidly metabolized.

PEA may produce short-lived mood and motivation effects through catecholamine-related signaling, but rapid MAO-B metabolism sharply limits duration. Some formulations combine PEA with MAO-B inhibitors, which can amplify both effects and risks. Minority claims include appetite and attention effects with limited support. Evidence for sustained benefits from standalone oral PEA use is weak and inconsistent.

Potent TAAR1 agonist that induces dopamine and norepinephrine release while inhibiting reuptake. Rapidly degraded by MAO-B (half-life ~5–10 min), rendering oral supplementation pharmacologically inert without MAO-B inhibition.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Endogenous trace amine that transiently stimulates dopamine and norepinephrine release via TAAR1 activation

Secondary Outcomes

  • Oral supplementation has near-zero bioavailability without concurrent MAO-B inhibition due to rapid metabolic degradation (~5–10 min half-life)

Safety

Contraindications and Interactions

Contraindications

  • Cardiovascular disease
  • Anxiety disorders
  • MAOI use
  • Severe hypertension
  • Schizophrenia

Side effects

  • Headache
  • Nausea
  • Anxiety
  • Tachycardia
  • Flushing
  • Jitteriness

Interactions

  • MAOIs (hypertensive crisis)
  • Selegiline (extends half-life, intended but requires medical oversight)
  • Stimulants (additive catecholamine effects)
  • SSRIs/SNRIs (serotonergic interactions)

Avoid if

  • Cardiovascular disease
  • Uncontrolled hypertension
  • Concurrent MAOI therapy

Evidence

Study-level References

phenylethylamine-pea-SRC-001Narrative review
Sourceopen_in_new

Berry MD. Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators. Journal of Neurochemistry. 2004;90(2). doi:10.1111/j.1471-4159.2004.02501.x. PMID:15228583.

Population: Review of mammalian CNS trace amine research

Dose protocol: Review of trace amines (2-phenylethylamine, tyramine, octopamine, tryptamine) and their physiological roles in the mammalian CNS

Key findings: PEA acts as an endogenous amphetamine, stimulating the release of dopamine and norepinephrine. Its therapeutic utility in isolation is fundamentally limited by its incredibly rapid metabolism by MAO-B, resulting in a half-life of less than 10 minutes.

Paper content

This review examines trace amines (phenylethylamine, tyramine, octopamine, tryptamine) in the mammalian CNS. Although these amines produce amphetamine-like effects at supraphysiological concentrations, such responses are unlikely to reflect their true function. The author hypothesizes that at physiological levels, trace amines serve as endogenous neuromodulators, altering neuronal sensitivity to classical monoamine neurotransmitters without changing baseline excitability.

Guides

Setup

Help